Rare tumors are addicted to single activated oncogenes, recently exemplified by bcr-abl in CML, ALK in 4% of NSCLC, and BRAF in certain melanomas [1]–[4], [24], [29]. This evidence concerns the gene BRAF and non-small cell lung carcinoma.